香港股市 已收市

TEVA Sep 2024 13.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
4.73000.0000 (0.00%)
收市:03:04PM EDT
全螢幕
前收市價4.7300
開市4.4000
買盤4.4000
賣出價4.6000
拍板13.00
到期日2024-09-20
今日波幅4.4000 - 4.8500
合同範圍
成交量18
未平倉合約2.46k
  • Reuters

    Teva sues Corcept over mifepristone 'monopoly' for rare disorder

    Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.

  • Zacks

    TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

    TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

  • InvestorPlace

    Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

    Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry. Yet it risks killing off the drug discovery market with its actions by disincentivizing companies to find new treatments. For example, inventors of technology developed with federal funding retain